CEO Miles White

Abbott Laboratories (ABT) (ABT) bid to expand use of its best-selling arthritis treatment Humira to ulcerative colitis patients is being delayed by U.S. regulators. We did receive a complete response letter several months ago and have provided additional information to the Food and Drug Administration, Elizabeth Hoff, a spokeswoman for the Abbott Park, Illinois-based company, said in an e-mail today...  

Hawaii has joined 44 other states and the District of Columbia in a $100 million settlement with Abbott Laboratories over the pharmaceutical company's promotion of the anti-seizure and mood-stabilizing drug Depakote. KITV reports Hawaii will receive nearly $1.2 million and Illinois-based Abbott (NYSE: ABT) will be restricted from marketing the drug for uses that are not approved by the U.S. Food and Drug Administration. The Associated Press...  

Florida will receive $5 million of a $100 million settlement with Abbott Laboratories over allegations of illegal off-label marketing of the drug Depakote. The $5 million will go toward future consumer protection efforts, Florida Attorney General Pam Bondi said in a written statement. Bondi and attorney generals from 44 other states alleged Abbott engaged in unfair and deceptive practices in marketing Depakote for off-label uses. The drug...  

By ValueMax:The pharmaceuticals industry is a defense play, just like the food and beverages industry, in terms of sensitivity and market beta. Abbott Laboratories (ABT) is uniquely situated in the industry because of its growth prospects and because it still has a reduced valuation due to lawsuit-related uncertainty. The month of May brought the end to a lawsuit filed against the company for marketing Depakote, a drug for schizophrenia, for...  

Tennessee will get $5 million more from the $1.6 billion settlement with Abbott Laboratories, The Tennessean reports. The additional $5 million is on top of $2 million that was announced Monday for the state. Illinois-based Abbott is making the massive payout to settle allegations that it deceptively marketed an anti-seizure drug, Depakote, for unapproved uses.  

FRANKFORT, Ky. (AP) -- Kentucky will receive $4.6 million as part of a legal settlement with Abbott Laboratories. Attorney General Jack Conway announced Kentucky's share from the settlement on Monday. The Illinois-based company agreed to pay $1 ...  

As Abbott Laboratories prepares to get down to basics as a consumer-products company, it is pinning its emerging-market ambitions in part on turmeric. And cumin and chili. Abbott, which will split with its 124-year-old research-based drug division later this year, is shifting its focus from breakthrough medicines like arthritis treatment Humira, which command high prices in developed markets, to more...  

Abbott Laboratories (ABT) has encountered a delay in its bid for U.S. regulatory approval to expand the uses of its blockbuster anti-inflammatory drug Humira to include treatment of the bowel disease ulcerative colitis. Abbott received a ...  

ABBOTT PARK, Ill. and AARHUS, Denmark, May 3, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) and Action Pharma A/S, a privately owned company, today announced that they have entered into an agreement in which Abbott will acquire AP214 from Action Pharma.AP214 is in development to prevent acute kidney injury (AKI) associated with major cardiac...  

Texas Attorney General Greg Abbott and other state attorneys general today resolved a two-phase Medicaid fraud and deceptive marketing investigation into Abbott Laboratories. The investigation centered on the unlawful promotional scheme that Abbott Laboratories launched to increase the sales of its anti-seizure drug Depakote.  

Drugmaker improperly marketed anti-seizure medication for off-label uses, or those not approved by the FDA Abbott Laboratories said Monday that it will pay $1.6 billion to settle federal and state claims that it illegally marketed the anti-seizure medication Depakote for uses not approved by the Food and Drug Administration.  

CHICAGO--(BUSINESS WIRE)--Fitch Ratings has placed Abbott Laboratories' (ABT's) Long-term ratings on Negative Watch. In addition, Fitch has affirmed ABT's Short-term ratings at 'F1'. A full list of ABT's ratings follows at the end of this press release.  

They will split about $84 million from the settlement, Heaphy said. The case was investigated by the Virginia Attorney General's Medicaid Fraud Control Unit and prosecuted by the U.S. attorney's office in Western Virginia because of their track records ...  

About Acute Kidney Injury Associated with Major Cardiac Surgery Acute kidney injury (AKI) is known to be associated with increased short- and long-term mortality and co-morbidity, as well as prolonged hospitalization and permanent decline in renal function.  

Abbott Laboratories Abbott Laboratories Latest from The Business Journals U.S. manufacturing picks up pace Accelr8 Technology to get major private-equity investment, new execs St. Jude Medical, Abbott Laboratories expand marketing partnership ...